News

FDA panel selectively recommends Merck antiviral COVID-19 pill

By Christopher Hutton
Published December 1, 2021 1:21pm ET
Add Washington Examiner on Google
FDA panel selectively recommends Merck antiviral COVID-19 pill
In this Thursday, Feb. 28, 2013 photo, a Merck logo is placed on scientist's lab coat in West Point, Pa. Merck & Co. reports quarterly financial results before the market opens on Wednesday, Feb. 5, 2014. (AP Photo/Matt Rourke) | Matt Rourke

A Food and Drug Administration panel has selectively recommended Merck’s COVID-19 antiviral pill, paving the way for approval.

A panel of doctors organized by the FDA voted 13-10 to recommend that the agency authorize Merck’s antiviral pill, named molnupiravir, for public use Tuesday, finding the known and potential benefits of the new treatment outweigh the possible risks.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

COVID-19 FDA Merck Pfizer